Neuron23 has dosed the first participant in its Phase 2 clinical trial of NEU-411, an investigational treatment for early Parkinson’s disease that targets overactivity in the LRRK2 enzyme. The therapy may benefit individuals with genetic mutations or variations in the LRRK2 gene, which is a key contributor and…
People with Parkinson’s disease have altered levels of certain fat molecules, known as lipids, in their brains, and this may play a role in disease development and progression, a new study from the U.S. reports. The researchers used postmortem brain tissue samples to analyze changes in lipids in 40…
A three-year grant from Parkinson Canada will allow a Canadian researcher to investigate the mechanisms by which a recently found mutation in the RAB32 gene is linked to Parkinson’s disease. The $135,000 grant will allow Jay Penney, PhD, associate professor at the University of Prince Edward Island in…
A new method that uses artificial intelligence (AI) to analyze the smell of earwax may help detect Parkinson’s disease, a new study from China reports. This affordable approach could one day be used to screen people for early signs of Parkinson’s, making it easier to catch the disease before…
VTX3232, an NLRP3 inhibitor being developed by Ventyx Biosciences as a treatment for Parkinson’s disease, was found to be safe and well tolerated after nearly one month of daily dosing in a clinical trial involving people with early-stage disease, according to the company. With these results, VTX3232 met…
Changes in the bacterial communities in the gut and mouth are associated with cognitive impairment in people with Parkinson’s disease, a study suggests. Some oral bacteria and related virulence factors, such as molecules that help bacteria colonize the body — many of which can trigger a potent inflammatory response…
Roche said it will launch a Phase 3 trial testing prasinezumab, an anti-alpha-synuclein antibody, as a potential treatment for early-stage Parkinson’s disease. The decision follows data from two Phase 2 trials showing prasinezumab had potential clinical efficacy at slowing motor symptom progression and reducing motor complications as an add-on…
A new clinical program will use ibogaine, a naturally occurring psychedelic, to treat neurodegenerative conditions including Parkinson’s disease. Ambio Life Sciences, which hosts other ibogaine programming and participates in scientific research about the drug, soft-launched the program in February. It is the first of its kind in the…
Aging interferes with the way neurons, or nerve cells, respond to stress, making them more susceptible to damage and more likely to contribute to neurodegenerative diseases such as Parkinson’s, according to a study in cells and brain tissue. “It’s the neuronal equivalent of being so stressed that you catch…
Researchers in Texas have discovered a promising therapeutic target for neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Using a mouse model of Alzheimer’s disease, they found that blocking the stress sensor GADD45G in astrocytes, which are star-shaped cells that support neurons, reduced the buildup of toxic proteins…
Get regular updates to your inbox.
